Targeting inhibitor of apoptosis proteins for cancer therapy: A double-edge sword?

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3190-3191

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBITOR OF APOPTOSIS PROTEIN; LCL 161; MESSENGER RNA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; THIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DEATH; CELL SURVIVAL; CYTOKINE RELEASE SYNDROME; HUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR GROWTH; UBIQUITINATION; FEMALE; MALE; NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASMS; THIAZOLES;

EID: 84907587199     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.8741     Document Type: Article

References (12)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
2. Fulda S, Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109-124, 2012
3. Varfolomeev E, Blankenship JW, Wayson SM, et al: IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalphadependent apoptosis. Cell 131:669-681, 2007
4. Vince JE, Wong WW, Khan N, et al: IAP antagonists target cIAP1 to induce TNFalphadependent apoptosis. Cell 131:682-693, 2007
5. Wang L, Du F, Wang X: TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133:693-703, 2008
6. Bertrand MJ, Milutinovic S, Dickson KM, et al: cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30:689-700, 2008
7. Fulda S, Wick W, Weller M, et al: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815, 2002
8. Infante JR, Dees EC, Olszanski AJ, et al: A phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:3103-3110, 2014
9. Tchoghandjian A, Jennewein C, Eckhardt I, et al: Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB. Cell Death Differ 21:735-747, 2014
10. Firestone B, Conway C, Yang G, et al: Correlation between TNF{alpha} and LCL161 anti-tumor activity in patient derived xenograft models of human cancer. Mol Cancer Ther 8:12, 2009 (suppl; abstr B27)
11. Steinhart L, Belz K, Fulda S: Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 4:e802, 2013
12. Amaravadi RK, Senzer NN, Martin LP, et al: A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J Clin Oncol 31, 2013 (suppl 15s; abstr 2504)